Systematic review and meta-analysis of anti-thymocyte globulin dosage as a component of graft-versus-host disease prophylaxis
PLOS ONE · 2023
DOI: 10.1371/journal.pone.0284476 ↗Kurz gefasst
Metaanalyse in der Zeitschrift PLOS ONE, 2023. Verfasst von Joice Zuckermann und 4 weiteren Autor:innen. Beteiligte Einrichtung: Graduate Program in Pharmacology and Therapeutics, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil. Hauptthemen laut MEDLINE: Epstein-Barr Virus Infections, Hematopoietic Stem Cell Transplantation, Graft vs Host Disease. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hospital de Clínicas de Porto Alegre.
Abstract (Originalsprache)
Rabbit anti-thymocyte globulin (ATG) has been used in allogeneic hematopoietic stem cell transplantation (Allo-HSCT) for graft-versus-host disease (GvHD) prophylaxis. Since the best dose has not been defined yet, this study aimed to determine the efficacy and safety of different doses of ATG in Allo-HSCT. Data sources were MEDLINE/PUBMED, EMBASE, Cochrane Library, Web of Science, LILACS, and SciELO. Studies were eligible when comparing doses of ATG. The higher dose was in the intervention group. A total of 22 articles (2002–2022) were included. Higher doses (4–12 mg/kg) of ATG-T reduced the incidence of grade III-IV acute GvHD (RR 0.60; 95%CI 0.42–0.84) and limited chronic GvHD (RR 0.64 95%CI 0.45–0.92) compared with lower doses (2–7.5 mg/kg). Higher doses increased the Epstein-Barr virus (RR 1.90 95% CI 1.49–2.42) and Cytomegalovirus reactivation (RR, 1.30; 95% CI 1.03–1.64). Relapse rates were higher in the higher dose group (RR 1.34, 95% CI 1.07–167). The ATG-T dose ≥7mg/kg versus the lower dose showed a number needed to treat 7.4 for acute GvHD III-IV, with a number to harm of 7.7 for relapse at one year in the higher dose group. A dose lower than 7 mg/kg suggests a better risk-benefit ratio than a higher one. Well-designed RCT is needed to define the best risk-benefit doses. Trial registration: Trial registration number: PROSPERO: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42020173449 .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Graduate Program in Pharmacology and Therapeutics, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.
- Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil.
- School of Medicine, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil.
- Nursing School, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil.
ORCID-Profile: Bruno Mateus de Castro, Leila Beltrami Moreira
Förderung
- Hospital de Clínicas de Porto Alegre
Zitieren
APA
Zuckermann, J., Castro, B. M., Cunha, T. A., Paz, A., & Moreira, L. B. (2023). Systematic review and meta-analysis of anti-thymocyte globulin dosage as a component of graft-versus-host disease prophylaxis. PLOS ONE. https://doi.org/10.1371/journal.pone.0284476
Vancouver
Zuckermann J, Castro BM, Cunha TA, Paz A, Moreira LB. Systematic review and meta-analysis of anti-thymocyte globulin dosage as a component of graft-versus-host disease prophylaxis. PLOS ONE. 2023. doi:10.1371/journal.pone.0284476
BibTeX
@article{Zuckermann2023,
author = {Zuckermann, Joice and Castro, Bruno Mateus de and Cunha, Thiago Almirante and Paz, Alessandra and Moreira, Leila Beltrami},
title = {Systematic review and meta-analysis of anti-thymocyte globulin dosage as a component of graft-versus-host disease prophylaxis},
journal = {PLOS ONE},
year = {2023},
doi = {10.1371/journal.pone.0284476}
}
EUVIMED